Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab or Merestinib Plus Cisplatin and Gemcitabine in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of ramucirumab and merestinib in biliary tract cancer (BTC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival up to 20 months. Started May 2016; status: active, not recruiting.
02
Drugs
ramucirumabmerestinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02711553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711553.